ETF Foundry
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
investment factor · long-only model fund

Foundry Healthcare Sales Discipline Factor ETF

ETF Foundry Research (hypothetical) · rebalanced monthly

FSAHHYPOTHETICAL MODEL
Since ’99
+75%
Expense Ratio
0.45%
placeholder
Holdings
73
cap-weighted
Inception
Jul 2020
placeholder
Full Sharpe
0.20
Ann. Return (LS)
3.9%
Ann. Volatility
19.4%
Max Drawdown
-53.1%
Test Sharpe ’19–26
0.27
Test FF5 α (ann.)
7.2%
vs Fama-French 5
Test FF5 α t-stat
0.92
not significant
Monthly turnover
15%
of the long leg, per rebalance
Cumulative return (LS)
75%
over 331 months
This fund holds the long leg only
Long leg Sharpe
0.48
what this fund holds
Long leg ann. return
9.7%
buyable, long-only
Long-short Sharpe
0.20
requires shorting
Bottom bucket ann. return
5.8%
the basket shorted

Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.

Hypothetical growth of $1 — long-short backtest

Gross of the placeholder expense ratio and trading costs · not investor results

331 months

Holdings

Every constituent of the long leg — sort, search or filter by sector

73 of 73 · 100.0% of book
TickerCompanySectorMarket capWeight
1ROIV
ROIVANT SCIENCES LTDHealthcare$24.82B
13.12%
2MRNA
MODERNA INCHealthcare$24.53B
12.97%
3BAX
BAXTER INTERNATIONAL INCHealthcare$11.68B
6.17%
4KYMR
KYMERA THERAPEUTICS INCHealthcare$9.52B
5.03%
5PTGX
PROTAGONIST THERAPEUTICS INCHealthcare$9.06B
4.79%
6PRAX
PRAXIS PRECISION MEDICINES INCHealthcare$8.77B
4.63%
7XENE
XENON PHARMACEUTICALS INCHealthcare$6.60B
3.49%
8PTCT
PTC THERAPEUTICS INCHealthcare$6.52B
3.45%
9TFX
TELEFLEX INCHealthcare$5.96B
3.15%
10DNTH
DIANTHUS THERAPEUTICS INCHealthcare$5.77B
3.05%
11CRSP
CRISPR THERAPEUTICS AGHealthcare$4.61B
2.44%
12ICUI
ICU MEDICAL INCHealthcare$3.94B
2.08%
13ALMS
ALUMIS INCHealthcare$3.65B
1.93%
14OGN
ORGANON & COHealthcare$3.55B
1.88%
15HAE
HAEMONETICS CORPHealthcare$3.54B
1.87%
16CLDX
CELLDEX THERAPEUTICS INCHealthcare$2.77B
1.47%
17IMNM
IMMUNOME INCHealthcare$2.53B
1.34%
18NRIX
NURIX THERAPEUTICS INCHealthcare$2.40B
1.27%
19PBH
PRESTIGE CONSUMER HEALTHCARE INCHealthcare$2.36B
1.25%
20NKTR
NEKTAR THERAPEUTICSHealthcare$2.31B
1.22%
21NEOG
NEOGEN CORPHealthcare$2.24B
1.18%
22AGL
AGILON HEALTH INCHealthcare$2.17B
1.15%
23MD
PEDIATRIX MEDICAL GROUP INCHealthcare$2.15B
1.13%
24GLUE
MONTE ROSA THERAPEUTICS INCHealthcare$2.07B
1.10%
25OCUL
OCULAR THERAPEUTIX INCHealthcare$1.96B
1.04%
26MRVI
MARAVAI LIFESCIENCES HOLDINGS INCHealthcare$1.87B
0.99%
27SRPT
SAREPTA THERAPEUTICS INCHealthcare$1.82B
0.96%
28STOK
STOKE THERAPEUTICS INCHealthcare$1.81B
0.96%
29ZYME
ZYMEWORKS INCHealthcare$1.77B
0.93%
30TDOC
TELADOC HEALTH INCHealthcare$1.70B
0.90%
31PSNL
PERSONALIS INCHealthcare$1.61B
0.85%
32PRGO
PERRIGO CO PLCHealthcare$1.48B
0.78%
33NVAX
NOVAVAX INCHealthcare$1.35B
0.71%
34XNCR
XENCOR INCHealthcare$1.30B
0.68%
35ABSI
ABSCI CORPHealthcare$1.29B
0.68%
36AZTA
AZENTA INCHealthcare$1.21B
0.64%
37QDEL
QUIDELORTHO CORPHealthcare$1.19B
0.63%
38CAPR
CAPRICOR THERAPEUTICS INCHealthcare$1.13B
0.60%
39WVE
WAVE LIFE SCIENCES LTDHealthcare$1.12B
0.59%
40EYPT
EYEPOINT INCHealthcare$1.12B
0.59%
41AVTX
AVALO THERAPEUTICS INCHealthcare$1.02B
0.54%
42AMPH
AMPHASTAR PHARMACEUTICALS INCHealthcare$871M
0.46%
43ACRS
ACLARIS THERAPEUTICS INCHealthcare$793M
0.42%
44CSTL
CASTLE BIOSCIENCES INCHealthcare$733M
0.39%
45EVH
EVOLENT HEALTH INCHealthcare$654M
0.35%
46STTK
SHATTUCK LABS INCHealthcare$577M
0.31%
47ARVN
ARVINAS INCHealthcare$517M
0.27%
48DNA
GINKGO BIOWORKS HOLDINGS INCHealthcare$517M
0.27%
49RGNX
REGENXBIO INCHealthcare$511M
0.27%
50NRC
NRC HEALTHHealthcare$491M
0.26%
51PRTA
PROTHENA CORP PUBLIC LTD COHealthcare$453M
0.24%
52PBYI
PUMA BIOTECHNOLOGY INCHealthcare$434M
0.23%
53CCRN
CROSS COUNTRY HEALTHCARE INCHealthcare$428M
0.23%
54EBS
EMERGENT BIOSOLUTIONS INCHealthcare$394M
0.21%
55LYEL
LYELL IMMUNOPHARMA INCHealthcare$311M
0.16%
56MASS
908 DEVICES INCHealthcare$278M
0.15%
57TRDA
ENTRADA THERAPEUTICS INCHealthcare$268M
0.14%
58SRZN
SURROZEN INCHealthcare$255M
0.13%
59RNAC
CARTESIAN THERAPEUTICS INCHealthcare$243M
0.13%
60RXST
RXSIGHT INCHealthcare$230M
0.12%
61SPOK
SPOK HOLDINGS INCHealthcare$222M
0.12%
62UTMD
UTAH MEDICAL PRODUCTS INCHealthcare$222M
0.12%
63KROS
KEROS THERAPEUTICS INCHealthcare$211M
0.11%
64DTIL
PRECISION BIOSCIENCES INCHealthcare$203M
0.11%
65AMWL
AMERICAN WELL CORPHealthcare$199M
0.11%
66KRRO
KORRO BIO INCHealthcare$177M
0.09%
67ARCT
ARCTURUS THERAPEUTICS HOLDINGS INCHealthcare$172M
0.09%
68JYNT
JOINT CORPHealthcare$127M
0.07%
69SPRB
SPRUCE BIOSCIENCES INCHealthcare$120M
0.06%
70ATRA
ATARA BIOTHERAPEUTICS INCHealthcare$76M
0.04%
71CLNN
CLENE INCHealthcare$76M
0.04%
72SCLX
SCILEX HOLDING COHealthcare$72M
0.04%
73AGPU
AXE COMPUTE INCHealthcare$72M
0.04%

Full long-leg book as of July 2026 · cap-weighted · total market cap $189.15B. Hypothetical model holdings — not a registered fund’s portfolio.

Sector Breakdown

1 sectors
Healthcare
100.0%

Portfolio Style

Size × value map of the long-leg book

73 classified
Value
Blend
Growth
Large
Mid
Small
15%2
27%5
12%3
10%10
11%10
2%2
4%19
1%3
1%4

Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 80% toward Large, 41% toward Growth. +19% unclassified (15 missing size/value). Hypothetical holdings — descriptive, not realized P&L.

Tilt over time
Size tilt80% → Large
SmallLarge
Value ↔ growth tilt41% → Growth
ValueGrowth

Capital-weighted centroid of the long leg, December 1998July 2026; the right-hand end is the same value as the box’s dot. 73 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.

Constraint checks

How this book measures against the concentration and liquidity rules — as implemented here

How this book was built

These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.

Passed
6
Failed
0
Not tested
1
Independent checks
7

7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.

1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.

Reported separately — arithmetically implied

Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.

No verdict sits within 1.0pp of its limit.

Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700

Measured on the 2026-07 formation date across 73 holdings (cap-weighted). A different formation date can produce different verdicts.

Derivatives risk (Rule 18f-4)

Whether this long-only book is subject to the VaR tests at all

This assessment describes the long-only book this fund holds — the top bucket only.

Governing rule
Rule 18f-4(c)(4) limited derivatives user exception

This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.

Limited derivatives user exceptionby construction

Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.

Qualifies
Required
<= 10% of net assets
Exposure
0% of net assets
Margin
+10pp

No confidence interval: this follows from portfolio construction, not from an estimate.

Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.

Informational — does not govern

This fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.

Measured
1.3 (95% CI 0.8-1.6)
x reference VaR
Limit
2.00x
<= 2.00x reference VaR
Fund VaR
13.0%
99% / 20d
Reference
9.6%
FF5 market (mkt)

historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months

Same test, three estimators
historical
1.34x
within
parametric
1.29x
within
cornish fisher
1.53x
within · unreliable

The estimators agree, which is mild evidence the number isn’t an artefact of one method.

Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.

The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.

See the long-short verdict on the factor page →

Since publication

Did the edge survive the paper coming out?

Publication date unknown. We don’t have a source year for this signal, so we can’t split its record into before and since publication. That’s a gap in our reference data — not a statement about how the factor performed.

Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.

Consistency across eras

Is this record broadly durable, or one regime?

26 windows
Positive windows
65%
17 of 26 3-year windows made money
Worst window
-0.72
Sharpe, January 2013 – December 2015
January 1999July 2026
Median Sharpe
0.12
Dispersion
0.45
Best window
0.97

3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.

Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.

Returns

Long leg is what this fund holds — long-short is shown for reference

since January 1999
Trailing
PeriodLong legLong-short
1 yearcum.74.2%7.6%
3 yearsp.a.16.2%1.6%
5 yearsp.a.6.1%6.4%
10 yearsp.a.7.3%1.7%
Since inceptionp.a.8.0%2.1%
Calendar years
YearLong legLong-short
20267 mo39.3%26.8%
202529.5%-13.1%
2024-9.0%-5.5%
2023-4.9%11.8%
2022-0.8%17.0%
2021-0.8%-7.9%
202039.9%27.5%
20199.8%-19.2%
2018-12.4%6.5%
20176.4%-18.3%
20161.4%11.6%
201510.8%-5.4%
201418.7%-10.3%
201334.2%-17.1%
201231.3%15.4%
20117.5%4.0%
201017.0%11.3%
200918.8%-12.6%
2008-16.2%13.6%
2007-3.8%-21.7%
200619.4%21.9%
20050.8%-17.8%
2004-4.6%3.4%
200317.3%-11.3%
2002-38.4%13.8%
2001-14.0%16.1%
200077.5%57.2%
19996.5%-0.1%

Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.

Fund Facts

Ticker (pseudo)FSAH
IssuerETF Foundry Research (hypothetical)
SeriesHypothetical Model Portfolio Series (not a registered trust)
Expense ratio0.45% (placeholder)
Inception2020-07-26 (placeholder)
Listing exchangeNot listed (hypothetical)
CUSIPNot applicable (hypothetical model portfolio)
RebalanceMonthly
Holdings as ofJuly 2026
Total mkt cap (long leg)$189.15B

Methodology

The Foundry Healthcare Sales Discipline Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Sales Discipline signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.

This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.

Documents (draft — hypothetical)

Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.

Summary Prospectus

Objective, fees, strategy, and key risks.

View →
Prospectus

Full strategy, model methodology, and risks.

View →
Statement of Additional Information

Policies, construction, and governance.

View →
Fact Sheet

One-page snapshot with top holdings.

View →
Daily Holdings

Full current constituent list.

View →

DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.